Bipolar Disorder Drugs And Treatment Global Market Report 2025

The bipolar disorder drugs and treatment market size has grown strongly in recent years. It will grow from $7.74 billion in 2024 to $8.24 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth observed in the historical period can be attributed to factors such as rising healthcare expenditures, increased research and funding for mental health, a growing number of healthcare professionals specializing in mental health, more early diagnoses of bipolar disorder, and an increasing demand for outpatient psychiatric care.

The bipolar disorder drugs and treatment market size is expected to see strong growth in the next few years. It will grow to $10.46 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The projected growth in the forecast period is driven by the rising global prevalence of bipolar disorder, greater awareness of mental health conditions, increasing acceptance of mental health treatment, broader insurance coverage for mental health care, and government initiatives aimed at improving mental health services. Key trends during this period include advancements in bipolar disorder drug development, improvements in diagnostic methods and tools, the introduction of new drug formulations, ongoing clinical trials and research on novel medications, and the availability of generic drugs for bipolar disorder.

The increasing prevalence of mental health disorders is expected to drive the growth of the bipolar disorder drugs and treatment market in the coming years. Mental health disorders are conditions that impact a person’s thoughts, feelings, behavior, or mood, often hindering daily functioning and overall well-being. The rise in mental health disorders can be attributed to chronic stress stemming from modern lifestyles, with ongoing pressures related to work, finances, and social expectations negatively affecting emotional health and leading to long-term psychological challenges. Bipolar disorder drugs and treatments play a vital role in stabilizing mood fluctuations, improving emotional regulation, and reducing the frequency and severity of disruptive episodes associated with these disorders. For example, in September 2024, the National Institute of Mental Health (NIMH) reported that over 59.3 million adults in the US were affected by any mental illness (AMI) in 2022, which accounted for 23.1% of the adult population. Additionally, women were more likely than men to experience AMI, with 26.4% of women affected compared to 19.7% of men. As mental health disorders continue to rise, the demand for bipolar disorder drugs and treatments will grow.

Key players in the bipolar disorder drugs and treatment market are focusing on the development of advanced solutions such as extended-release injectable formulations, which offer consistent and long-term therapeutic effects. These formulations slowly release medication into the bloodstream over time, reducing the need for daily doses and ensuring stable therapeutic outcomes. For example, in January 2023, Luye Pharma, a China-based pharmaceutical company, received FDA approval for Rykindo (risperidone), a long-acting injectable treatment for adult schizophrenia and bipolar I disorder. This drug, which utilizes a unique microsphere technology platform developed by Luye Pharma, is administered via an intramuscular injection every two weeks, providing long-lasting effects. The active ingredient, risperidone, is delivered using the extended-release microsphere technology to ensure sustained release over time.

In April 2025, Johnson & Johnson, a US-based healthcare company, acquired Intra-Cellular Therapies Inc. for an undisclosed amount. This acquisition expands Johnson & Johnson’s portfolio, adding CAPLYTA (lumateperone), a once-daily oral therapy approved for the treatment of schizophrenia and the first FDA-approved treatment for bipolar depression. The acquisition also includes ITI-1284, a promising Phase 2 compound being investigated for generalized anxiety disorder (GAD) and Alzheimer’s disease-related psychosis and agitation. This deal strengthens Johnson & Johnson’s clinical pipeline and supports its strategic focus on mental health and related therapeutic areas. Intra-Cellular Therapies Inc. is a US-based provider of bipolar disorder drugs and treatments.

Major players in the bipolar disorder drugs and treatment market are Pfizer Inc., Johnson & Johnson, Merch & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Otsuka Holdings Co. Ltd., Astellas Pharma Inc., Sumitomo Pharma America Inc., Dr. Reddy's Laboratories Ltd., H. Lundbeck A/S, Cipla Limited, Gedeon Richter Plc, Lupin Limited, Neurocrine Biosciences Inc., and Alkermes Plc.

North America was the largest region in the bipolar disorder drugs and treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in bipolar disorder drugs and treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the bipolar disorder drugs and treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Bipolar disorder drugs and treatments involve a comprehensive approach aimed at managing significant mood swings and promoting long-term mental stability. This approach focuses on regulating brain function to reduce the severity and frequency of mood episodes, while also addressing related issues such as disrupted sleep, anxiety, and difficulties with concentration.

The primary treatments for bipolar disorder include mood stabilizers, anticonvulsants, antipsychotic drugs, antidepressants, and anti-anxiety medications. Mood stabilizers are designed to help maintain a stable mood, preventing the extreme highs (mania) and lows (depression) associated with bipolar disorder. These drugs can be administered through various methods, including oral, parenteral, and other routes, and are used to treat bipolar I disorder, bipolar II disorder, and cyclothymic disorder. They are available through multiple distribution channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

The bipolar disorder drugs and treatment market research report is one of a series of new reports that provides bipolar disorder drugs and treatment market statistics, including bipolar disorder drugs and treatment industry global market size, regional shares, competitors with a bipolar disorder drugs and treatment market share, detailed bipolar disorder drugs and treatment market segments, market trends and opportunities, and any further data you may need to thrive in the bipolar disorder drugs and treatment industry. This bipolar disorder drugs and treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The bipolar disorder drugs and treatment market consists of revenues earned by entities by providing services such as research and development, medical consultation services, mental health counseling support, and telehealth services. The market value includes the value of related goods sold by the service provider or included within the service offering. The bipolar disorder drugs and treatment market also includes sales of wearable monitoring devices, home diagnostic kits, cognitive assessment devices, and neurostimulation devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.